AR058805A1 - Derivados biciclicos de piridina utiles como agentes antipsicoticos - Google Patents
Derivados biciclicos de piridina utiles como agentes antipsicoticosInfo
- Publication number
- AR058805A1 AR058805A1 ARP060103894A ARP060103894A AR058805A1 AR 058805 A1 AR058805 A1 AR 058805A1 AR P060103894 A ARP060103894 A AR P060103894A AR P060103894 A ARP060103894 A AR P060103894A AR 058805 A1 AR058805 A1 AR 058805A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- heteroaryl
- aryl
- alkoxy
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- -1 = O Chemical group 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporcionan compuestos de la formula (1) o una sal farmacéuticamente aceptable de los mismos en la que X representa un átomo de nitrogeno; Y representa -C(H2)-, (-C(CH2), -S(O2)- o -C(=O)-, Z representa -C(H2)-, -S(O2)-, -N(Rz)-, o un átomo de oxígeno o azufre; A representa hidrogeno o -CH2OH; Rz representa hidrogeno, alquilo C1-6, alcoxi C1-6, -COR7 o -SO2R7; R1 representa halogeno, alquilo C1-6, alcoxi C1-6, =O, haloalquilo C1-6, haloalcoxi C1-6, hidrofilo o -CH2OH; m representa un numero entero de 0 a 3; R2 representa halogeno, =O, alquilo C1-6 (opcionalmente sustituido con uno o más grupos hidroxilo), -COOR7, CONR7R8, alcoxi C1-6, haloalquilo C1-6, haloalcoxi C1-6 o (alquil C1-6)O-alquilo C1-6; n representa un numero entero de 0 a 3; p y q independientemente representan un numero entero de 0 a 2; R3 representa un grupo -arilo, -heteroarilo, -heterociclilo, -aril-arilo, aril-heteroarilo, -aril-heterociclilo, -heteroaril-arilo, -heteroaril-heteroarilo, -heteroaril- heterociclilo, -heterociclil-arilo, -heterociclil-heteroarilo o -heterociclil-heterociclilo, todos los cuales pueden estar opcionalmente sustituidos con uno o más, (por ejemplo 1, 2 o 3) grupos halogeno, alquilo C1-6 (opcionalmente sustituido con uno o más grupos hidroxilo), cicloalquilo C3-8, alcoxi C1-6, hidroxilo, haloalquilo C1-6, haloalcoxi C1-6, ciano, -S-alquilo C1-6, -SO-alquilo C1-6, -SO2-alquilo C1-6, -COR7, -CONR7R8, -NR7R8, -NR7CO-alquilo C1-6, -NR7SO2-alquilo C1-6 (alquil C1-6)- NR7R8, -OCONR7R8, -NR7CO2R8 o -SO2NR7R8; R4 y R5 independientemente representan alquilo C1-6, o R4 y R5 junto con el átomo de carbono al que están unidos pueden formar un grupo cicloalquilo C3-8; R6 representa halogeno, alquilo C1-6, cicloalquilo C3- 8, alcoxi C1-6, haloalquilo C1-6 o haloalcoxi C1-6; s representa un numero entero de 0 a 4; R7 y R8 independientemente representan hidrogeno, alquilo C1-6 o cicloalquilo C3-8; o sus solvatos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0518472A GB0518472D0 (en) | 2005-09-09 | 2005-09-09 | Novel compounds |
| GB0611153A GB0611153D0 (en) | 2006-06-06 | 2006-06-06 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058805A1 true AR058805A1 (es) | 2008-02-27 |
Family
ID=37546936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103894A AR058805A1 (es) | 2005-09-09 | 2006-09-07 | Derivados biciclicos de piridina utiles como agentes antipsicoticos |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US7683056B2 (es) |
| EP (2) | EP2336136A1 (es) |
| JP (1) | JP5121716B2 (es) |
| KR (1) | KR101292348B1 (es) |
| AR (1) | AR058805A1 (es) |
| AT (1) | ATE505472T1 (es) |
| AU (1) | AU2006289281B2 (es) |
| BR (1) | BRPI0615787B8 (es) |
| CA (1) | CA2621564C (es) |
| CR (1) | CR9847A (es) |
| CY (1) | CY1111907T1 (es) |
| DE (1) | DE602006021323D1 (es) |
| DK (1) | DK1928886T3 (es) |
| EA (1) | EA013909B1 (es) |
| HR (1) | HRP20110457T1 (es) |
| IL (1) | IL189578A (es) |
| JO (1) | JO2722B1 (es) |
| MA (1) | MA29780B1 (es) |
| MY (1) | MY145713A (es) |
| NO (1) | NO340921B1 (es) |
| NZ (1) | NZ565983A (es) |
| PE (1) | PE20070614A1 (es) |
| PL (1) | PL1928886T3 (es) |
| PT (1) | PT1928886E (es) |
| SI (1) | SI1928886T1 (es) |
| TW (1) | TWI378101B (es) |
| WO (1) | WO2007028654A1 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039123A2 (en) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| WO2007042250A1 (en) * | 2005-10-10 | 2007-04-19 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| SI2404919T1 (sl) | 2005-11-08 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| JP2010516731A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物 |
| CA2684105C (en) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
| JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒのモジュレーター |
| PT2231606E (pt) | 2007-12-07 | 2013-05-17 | Vertex Pharma | Processos para a produção de ácidos cicloalquilcarboxiamido-piridina benzóicos |
| ES2993060T3 (en) | 2007-12-07 | 2024-12-20 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| ES2454366T3 (es) * | 2008-02-22 | 2014-04-10 | Neurotune Ag | Compuestos bicíclicos que contienen nitrógeno activos en afecciones de dolor crónico |
| CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
| WO2009119528A1 (ja) * | 2008-03-24 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| GB0808747D0 (en) * | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| US20110034469A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Heterocyclic Compound |
| CA2772168C (en) * | 2009-08-27 | 2019-01-08 | Glaxosmithkline Llc | Anhydrate forms of a pyridine derivative |
| WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
| HUE056525T2 (hu) | 2010-04-07 | 2022-02-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása |
| EP2590953B1 (en) | 2010-07-09 | 2014-10-29 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| WO2013049164A1 (en) * | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
| UY34349A (es) | 2011-09-29 | 2013-04-05 | Abb Vie Inc | OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO |
| US9029361B2 (en) | 2012-12-12 | 2015-05-12 | Abbvie Inc. | Agents for treating pain and uses thereof |
| PL3067349T3 (pl) | 2013-11-08 | 2018-06-29 | Kissei Pharmaceutical Co., Ltd. | Pochodna karboksymetylopiperydyny |
| SI3068392T1 (sl) | 2013-11-12 | 2021-07-30 | Vertex Pharmaceuticals Incorporated | Postopek za pripravo farmacevtskih sestavkov za zdravljenje bolezni, ki jih posreduje CFTR |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| WO2016021562A1 (ja) * | 2014-08-06 | 2016-02-11 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
| ES2882656T3 (es) | 2014-11-18 | 2021-12-02 | Vertex Pharma | Proceso para realizar pruebas de alto rendimiento de cromatografía líquida de alta resolución |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| DK3297631T3 (da) * | 2015-05-18 | 2019-11-11 | Nerre Therapeutics Ltd | NK-1/NK-3-receptorantagonist til behandling af hedeture |
| EP3691634A4 (en) | 2017-10-05 | 2021-03-31 | Biogen Inc. | PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES |
| KR20200139138A (ko) | 2018-03-14 | 2020-12-11 | 칸디 테라퓨틱스 리미티드 | 이중 nk-1/nk-3 수용체 길항제를 포함하는 신규한 제약 제제 |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| JOP20220111A1 (ar) | 2019-11-15 | 2023-01-30 | Kandy Therapeutics Ltd | عملية كيميائية جديدة لتشكيل 6-كلورو-4- (4-فلورو-2-مثيل فنيل) بيريدين-3-أمين بصفته مركباً وسيطاً رئيسياً لـ nt-814 |
| WO2021261969A1 (ko) * | 2020-06-26 | 2021-12-30 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| KR102682775B1 (ko) * | 2020-06-26 | 2024-07-08 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| US20240115539A1 (en) * | 2021-04-05 | 2024-04-11 | The Board Of Trustees Of The Leland Stanford Junior University | Enantiomer selective action on neurotransmission |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921855A (en) | 1987-06-22 | 1990-05-01 | Fujisawa Pharmaceutical Co., Ltd. | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same |
| US5166203A (en) | 1990-08-30 | 1992-11-24 | Kanebo, Ltd. | Quinolinecarboxylic acid derivatives, antibacterial agent containing the same |
| SI1004583T1 (en) | 1998-11-23 | 2004-12-31 | Pfizer Products Inc. | Process and hydantoin intermediates for the synthesis of growth hormone secretagogues |
| DK1035115T3 (da) | 1999-02-24 | 2005-01-24 | Hoffmann La Roche | 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister |
| GT200000203A (es) | 1999-12-01 | 2002-05-24 | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| PT1643998E (pt) | 2003-07-03 | 2007-11-21 | Hoffmann La Roche | Antagonistas duplos dos receptores de nc1/nc3 para tratar a esquizofrenia |
-
2006
- 2006-09-07 AR ARP060103894A patent/AR058805A1/es active IP Right Grant
- 2006-09-07 MY MYPI20064110A patent/MY145713A/en unknown
- 2006-09-07 PE PE2006001077A patent/PE20070614A1/es not_active Application Discontinuation
- 2006-09-07 DE DE602006021323T patent/DE602006021323D1/de active Active
- 2006-09-07 BR BRPI0615787A patent/BRPI0615787B8/pt active IP Right Grant
- 2006-09-07 SI SI200631047T patent/SI1928886T1/sl unknown
- 2006-09-07 CA CA2621564A patent/CA2621564C/en active Active
- 2006-09-07 WO PCT/EP2006/008845 patent/WO2007028654A1/en active Application Filing
- 2006-09-07 JP JP2008529564A patent/JP5121716B2/ja active Active
- 2006-09-07 EP EP10190918A patent/EP2336136A1/en not_active Withdrawn
- 2006-09-07 DK DK06777183.2T patent/DK1928886T3/da active
- 2006-09-07 EP EP06777183A patent/EP1928886B1/en active Active
- 2006-09-07 EA EA200800784A patent/EA013909B1/ru unknown
- 2006-09-07 NZ NZ565983A patent/NZ565983A/en not_active IP Right Cessation
- 2006-09-07 TW TW095132989A patent/TWI378101B/zh active
- 2006-09-07 AU AU2006289281A patent/AU2006289281B2/en active Active
- 2006-09-07 JO JO2006301A patent/JO2722B1/en active
- 2006-09-07 PT PT06777183T patent/PT1928886E/pt unknown
- 2006-09-07 US US12/065,923 patent/US7683056B2/en active Active
- 2006-09-07 KR KR1020087008441A patent/KR101292348B1/ko active IP Right Grant
- 2006-09-07 PL PL06777183T patent/PL1928886T3/pl unknown
- 2006-09-07 AT AT06777183T patent/ATE505472T1/de active
-
2008
- 2008-02-18 IL IL189578A patent/IL189578A/en active IP Right Grant
- 2008-03-17 MA MA30749A patent/MA29780B1/fr unknown
- 2008-03-28 CR CR9847A patent/CR9847A/es not_active Application Discontinuation
- 2008-04-07 NO NO20081728A patent/NO340921B1/no unknown
-
2009
- 2009-12-14 US US12/636,849 patent/US7919491B2/en active Active
-
2011
- 2011-02-23 US US13/032,740 patent/US8097618B2/en active Active
- 2011-06-17 HR HR20110457T patent/HRP20110457T1/hr unknown
- 2011-07-04 CY CY20111100641T patent/CY1111907T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058805A1 (es) | Derivados biciclicos de piridina utiles como agentes antipsicoticos | |
| ECSP10010060A (es) | Derivados de pirazol sustituídos | |
| NO2021002I1 (no) | Lefamulin, salter og solvater derav | |
| BRPI0616393B8 (pt) | compostos heterocíclicos fundidos úteis como moduladores de quinase, composição farmacêutica e usos dos mesmos | |
| ATE464355T1 (de) | Modifizierte farbmittel und modifizierte farbmittel enthaltende farbstrahltintenzusammensetzungen | |
| ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
| AR059136A1 (es) | Derivados de indol-3-il-carbonil-espiro-piperidina | |
| EA200800482A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| DOP2010000046A (es) | Compuestos de biciclolactama sustituida | |
| DE602005018929D1 (de) | Tintenbehälter, tintenstrahlaufzeichnungsverfahren und tintenbehälterregenerierungsverfahren | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| CO5700736A2 (es) | Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
| CO6140059A2 (es) | Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3) | |
| AR072971A1 (es) | Derivados de acilaminobenzamida utiles como pesticidas | |
| CO6210825A2 (es) | Derivado de heterocicliden-n-(aril)acetamina | |
| BR112012007069A2 (pt) | derivado de fenol | |
| CO6180507A2 (es) | Derivado de 2-piridincarboxamida que tiene efecto activador de gk | |
| CO5640135A2 (es) | Derivados de 4-(4-(heterociclilalcoxi)-1-(heterociclil-carbonil)piperidina y compuestos relacionados como antagonistas de histamina h3 para el tratamiento de enfermedades neurologicas tales como alzheimer | |
| PA8605301A1 (es) | Nuevos compuestos | |
| PE20080427A1 (es) | Agentes antivirales | |
| BR0317970A (pt) | Derivados de benzoìla substituìdos como herbicidas | |
| CO5721005A2 (es) | Triazolopirimidinas | |
| BRPI0113837B8 (pt) | compostos mutilinas com atividade antimicrobiana e composição farmacêutica que os compreende | |
| ATE485299T1 (de) | Tricyclische benzopyranverbindungen als antiarrhythmika | |
| ATE412038T1 (de) | Tintenstrahltinte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |